Aldeyra Therapeutics, Inc.
ALDXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Aldeyra Therapeutics, Inc. focuses on Biotechnology services and products. Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. The company carries a $105.6M market cap, placing it firmly in the micro-cap category. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Market Cap
$105.6M
Beta
1.15
P/E (TTM)
—
P/E (Fwd)
-8.75
EPS (TTM)
$-0.46
EPS (Fwd)
$-0.20
ROE
-51.8%
ROA
-22.2%
Cash
$65.0M
Total Debt
$15.5M
Free CF
-$19.6M
52W Change
-67.3%
Annual Financials
Cash vs Debt
Where ALDX stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ALDX finished 40.06% below its 150-day moving average ($3.22) and 47.98% below its 200-day moving average ($3.71). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALDX overbought or oversold?
At the July 15, 2026 close, ALDX's RSI(14) was 47.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Aldeyra Therapeutics, Inc. holds $65.0M in cash against $15.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$19.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -51.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ALDX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.